Abstract
Overview
Introduction
The generics market is undergoing significant change, with intense merger and
acquisition activity, a raft of upcoming patent expiries and new legislation
being enacted to promote generic prescription in the major markets. In
addition, key issues, such as authorized generics, the first biosimilars
approvals and increasing competition within the market are also affecting
growth dynamics
Scope
- Overview of the size of the generics market in the US, Japan, France,
Germany, Italy, Spain and the UK
- Assessment of the various policies being implemented to promote generic
prescribing and drug use
- Analysis of key strategic issues including M&A, authorized generics and
patent challenges
- Examination of the future areas for generic growth, including an update of
the biosimilars situation
Highlights
There is still room for growth in the more mature generics markets, with
governments examining methods of increasing generic usage even further.
However, pricing pressures may result in this growth not being translated into
positive returns for the generics industry.
Competition in the generics market is becoming increasingly intense, with low
cost producers expanding globally and branded Pharma becoming involved through
subsidiaries or via authorized generic agreements. The wave of consolidation
that swept through the generics market has been spurred on by this competition
and is unlikely to end any time soon.
The biosimilars market has moved on in 2006, with two products (Sandoz's
Omnitrope and Biopartners' Valtropin) being approved in the EU. Omnitrope was
finally approved in the US, after a lengthy delay, but the FDA has stated that
this does not set a precedent for future approvals of other biosimilars.
Reasons to Purchase
- Identify the key factors and issues that will either promote or prevent
generic growth in each of the seven major markets
- Understand the changing competitive dynamics within the generics industry
and plan your own strategies accordingly
- Assess the strategic issues that are affecting the generics industry and
how the key players are addressing them
| 
View Cart
